< Arab Finance - News - Rameda’s sales up 32.8% in 8 months
Count Down to relaunch

Rameda’s sales up 32.8% in 8 months

Rameda’s sales up 32.8% in 8 months

ArabFinance: Sales of Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) rose by 32.8% year-on-year during the first eight months of 2021, recording EGP 816 million, sources at the pharmaceutical sector told Souq Al Dawaa.

Accordingly, Rameda has a market share of 1.5%, ranking the 19th among pharmaceutical companies in terms of sales, the sources revealed.

As for August 2021, the company generated sales of EGP 113 million through pharmacies, with a market share 1.4%.

Moreover, the company’s sales hit EGP 1.181 billion during the period starting August 2020 until August 2021, with a growth rate of 34%.

Regarding the Egyptian pharmaceutical market, sales of the private sector increased by 11.9% to EGP 7.669 billion in August 2021.

During the first eight months of 2021, the pharmaceutical market recorded sales of EGP 53.8 billion, with a growth rate of 6.2%.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.

It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

#Related keywords


Recommended Stocks

13 Jun 2022
Delta Sugar SUGR

All rights reserved to Arab Finance 2020 ©

Back to top